MedTrace Logo

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

NCT04425187 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-06-12

No results posted yet for this study

Summary

To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.

Conditions

  • PFS

Interventions

DRUG

Gefitinib

gefitinib 250mg (1 tablet), once a day，PO

DRUG

Bevacizumab Combined With Gefitinib

Bevacizumab Combined With Gefitinib

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04425187 on ClinicalTrials.gov